PROCEPT BioRobotics stock hit a 52-week low after missing Q4 earnings and cutting 2026 guidance despite revenue growth.

PROCEPT BioRobotics (PRCT) stock dropped to a 52-week low of $19.35 on February 26, 2026, after reporting Q4 2025 results that missed revenue and earnings expectations, with revenue of $76.38 million and a loss of $0.53 per share, below forecasts of $93.70 million and a loss of $0.32. Despite a 12% year-over-year revenue increase and a 2026 revenue guidance of $390–$410 million, Q1 2026 guidance fell short, triggering a sell-off. Analysts issued mixed ratings, with downgrades from Bank of America, Piper Sandler, and Oppenheimer, while UBS and Jefferies maintained positive outlooks. The company, which develops robotic systems for benign prostatic hyperplasia, has a market cap of $1.2 billion and is majority-owned by institutions.